CDC Weekly Snapshot Shows Respiratory Virus Activity High

As of January 5, 2024, CDC is reporting that respiratory illness is increasing across the country. The levels are generally high in almost all regions.

“Activity Levels Update:

  • The amount of respiratory illness (fever plus cough or sore throat) causing people to seek healthcare is elevated or increasing across most areas of the country. This week, 39 jurisdictions experienced high or very high activity.
  • Nationally, emergency department visits due to influenza and COVID-19 are elevated in all age groups and increasing in all but school-aged children. Recent, holiday-related school closures and associated changes in healthcare seeking behavior may be impacting trends in influenza- and COVID-19-related visits among school-aged children. RSV-related emergency department visits decreased slightly nationally.
  • Nationally, COVID-19 wastewater viral activity levels and test percent positivity—indicators for infection levels—are higher than the same time last year (currently estimated as being 27% higher and 17% higher, respectively). However, indicators for illness requiring medical attention are lower, including emergency department rates being 21% lower than the same time last year.”

What’s Up with Seasonal Vaccines This Fall?

I just read an interesting article in JAMA on this fall’s Covid-19 vaccine. Most of it is from the FDA meeting in June (Rubin R. This Fall’s COVID-19 Vaccines Will Target Omicron XBB Subvariants, but Who Needs Them Remains to Be Seen. JAMA. Published online July 05, 2023. doi:10.1001/jama.2023.10053).

One expert was quoted, indicating that there will be “…an elaborate discussion” at the CDC ACIP meeting about who should get the new monovalent XBB.1.5 vaccine. I don’t see that the meeting is scheduled yet.

There are some other interesting quotes to pass along:

“Back in March and the first half of April, XBB.1.5 represented more than 80% of circulating SARS-CoV-2 in the US, according to CDC estimates. Its dominance began to slip in late April, and as of late June, XBB.1.5 represented little more than a quarter of circulating SARS-CoV-2 variants. By then, though, XBB.1.5 and 9 other XBB subvariants together accounted for a total of 96% of circulating SARS-CoV-2 in the US. Fortunately, members of the XBB family of subvariants are antigenically similar to each other, so a vaccine against XBB.1.5 should protect against the rest of them as well, the WHO committee noted.”

“By the third quarter of 2022, an estimated 96.4% of approximately 143 000 blood donors in a nationwide, longitudinal cohort had SARS-CoV-2 antibodies from previous infection or vaccination or both, according to an analysis published in June in Morbidity and Mortality Weekly Report.

Or, as Sawyer told JAMA, “[t]he whole US has had this virus in one form or another.”

Because of the high prevalence of SARS-CoV-2 antibodies in the population, Paul Offit, MD, in an interview predicted “a focused recommendation by the CDC” regarding who should receive the XBB.1.5 vaccine.”

“Offit said he expects that the CDC will recommend the new monovalent XBB.1.5 vaccine for groups at the greatest risk for severe disease, reflected in continuing hospitalizations for COVID-19. Those groups likely would include people who are 75 years or older, people with severely compromised immune systems, and pregnant people, Offit said.”

“At least for people 60 years or older, the fall vaccine situation will be more complicated than it was a year earlier, Schaffner noted. That’s because at its regular monthly meeting in June, ACIP voted to recommend that this age group have the option of being vaccinated against respiratory syncytial virus (RSV) after consulting with their physician or pharmacist.”

That would mean that there would be 3 vaccines coming in the fall: RSV, Covid-19, and influenza. Sena and I have been doubtful about why a conversation with a physician would be necessary for the RSV vaccine. We don’t know whether that means you couldn’t get it without a physician’s order. There are also questions about coadministration of the RSV and Covid-19 vaccines.

Because the time is coming soon for seasonal vaccines, we’re hoping the questions will be answered soon.

CDC ACIP Meeting Today on Vaccines

The ACIP meeting on several vaccines begins today and runs through Friday, 8:00 a.m-5:30 p.m. on the 21st-22nd and 8:00 a.m.-12:40 p.m. on the 23rd, ET.

The committee will discuss vaccines for Respiratory Syncytial Virus in adults, Polio, and Influenza vaccines on the 21st. There will be a vote for each.

They will discuss vaccines for Pneumococcal, Dengue, Chikungunya, Respiratory Syncytial Virus (pediatric and maternal) on the 22nd. They will vote on the pneumococcal vaccine.

They will discuss Mpox, Meningococcal, and Covid-19 vaccines on the 23rd.

CDC Advisory Committee Recommends Including Covid-19 Vaccine for Routine Immunization Schedule

Today, the CDC Advisory Committee on Immunization Practices recommended adding Covid-19 immunization to the routinely recommended vaccine schedule.